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This article discusses recent guidelines and management of
common respiratory conditions and reviews key papers
published over the past five years.
Asthma
The incidence and prevalence of this common chronic
condition has risen over the past few decades both in developed
and developing countries.  Acute asthma is responsible for 1000
deaths a year in the United Kingdom.
ß-agonists and oral or parenteral corticosteroids remain the
main drugs used in acute attacks.  Guidelines recommend
treatment with ipratropium and aminophylline in cases that do
not respond to first-line treatment.1
Magnesium has been shown to have a bronchodilatory effect
in patients with asthma.  Trials have revealed variable results
and further data will be more helpful to determine its role.
Nonetheless, it has been recommended in patients with acute
asthma and a severely reduced FEV1 who have not responded
to conventional treatment.1   It may be given as an intravenous
infusion of magnesium sulphate at a dose of 1.2-2g over twenty
minutes. 2
The role of newer drugs, such as leukotriene receptor
antagonists is being studied.  Studies have shown that when
intravenous monteleukast in the 7 or 14 mg dose was given with
standard treatment, there was a more rapid recovery in FEV1
over a two hour period as compared to placebo.   Zafirlukast
reduced the risk of relapse over a one month period when given
together with standard treatment.  It must be noted that
ipratropium was not included as part of the standard treatment.
Further data are needed before either of these agents can be
included in the guidelines. 1
Inhaled corticosteroids have become standard treatment for
the control of chronic asthma.  The dose response curve for the
effect of inhaled corticosteroids on lung function becomes flat
only at moderate doses, thus showing that higher doses worsen
the overall therapeutic ratio.  This has led to the use of lower
doses of inhaled steroids together with inhaled long-acting ß-2
agonists.  The addition of the latter has been found to be more
effective in the control of mild, moderate and severe asthma
rather than increasing the dose of inhaled corticosteroid.  This
also leads to a decrease in local and systemic side effects
associated with steroid treatment.1
   Leukotriene receptor antagonists have been recommended
in the UK asthma guidelines for those patients who despite
treatment with both inhaled corticosteroids and long acting ß-
2 agonists, remain symptomatic (Step 4).1
The role of anti-immunoglobulin E in asthma has also been
studied.  The effect of a recombinant humanised monoclonal
antibody, omalizumab given to 405 patients suffering from both
allergic asthma and allergic rhinitis was observed in a double
blind study carried out.  Patients were randomly given a placebo
or parenteral anti-immunoglobulin E over 24 weeks.  Subjects
chosen had elevated serum IgE levels and at least one positive
skin-prick test.  Those receiving the anti-immunoglobulin were
found to have fewer exacerbations of asthma.  In a separate study
patients with poorly-controlled moderate to severe allergic
asthma were given omalizumab at four weekly intervals for a
year.  Reduction in exacerbation rates and improvement in
symptom scores and ventilatory function were noted in patients
receiving the treatment.  More studies will be required for this
treatment to become standard. 1  It is important to note that
this is a very expensive from of therapy costing around US$
15,000 per patient per year.
Newer treatments may focus on the use of antibodies to
interleukin 5 and 12, though as yet trials have not been very
promising. 1
Certain studies have suggested that chronic and recurrent
pulmonary inflammation in asthma may lead to remodelling of
the airways and irreversible airflow obstruction. In one such
study carried out in the Netherlands 136 non-smoking asthma
patients were enrolled.  All had received long-acting inhaled
bronchodilator therapy and inhaled corticosteroids for at least
one year.  Some were taking pulse steroid therapy and a few
were on continuous oral steroid therapy for disease control.  The
patients were investigated using spirometry, airway
responsiveness to histamine and by measuring the eosinophil
count in both peripheral blood and expectorated sputum. Of
these patients 48.5% were found to have persistent airflow
obstruction that is a post-bronchodilator FEV1/FVC ratio less
than 75% of the predicted value. Associations between persistent
airflow obstruction and older age, longer duration of asthma,
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greater response to histamine and a higher eosinophil count in
the sputum were noted.  These patients had less exacerbations
of asthma in the previous year which may suggest a decrease in
disease variability with time.
This opens the debate of whether progression of asthma to
irreversible airflow obstruction can be prevented or delayed by
more aggressive treatment than is necessary for symptom
control.  Further studies are necessary to confirm this. 3,8
Chronic obstructive pulmonary disease
(COPD)
Physicians may be failing to recognize mild COPD and in
certain cases even considerable lung impairment.  This
information was derived from the Third National Health and
Nutrition Examination Survey of 20,000 US adults.
In the study airflow obstruction was defined as an FEV1/
FVC ratio below the lower limit of normal.  Values were matched
for age.  90% of those with undiagnosed obstructive lung disease
had a mild condition with the above ratio just below the lower
limit of normal.  In 50% of the patients with undiagnosed
obstructive lung disease the FEV1 was more severely reduced,
at less than 75% of the predicted value.
Undiagnosed obstructive lung disease impairs both health
and function in patients.  This data should raise awareness
among physicians when faced with patients reporting dyspnoea
or feelings of ill-health.  Screening for COPD with spirometry
was recommended for at risk patients, especially smokers. 4,8
Four randomised, controlled multi-centre trials were carried
out to determine the effect of inhaled steroids on disease
progression in COPD.  Results were similar for all trials.  In one
such study current or recently abstinent smokers were
randomised to receive either a high dose of triamcinolone, six
inhalations twice a day, or an inhaled placebo.
Inhaled steroids were not found to decrease disease
progression in mild to moderate COPD, in patients who had
recently stopped smoking and in smokers.  They were found,
however, to modestly improve symptoms of dyspnoea and
decrease frequency of exacerbations.  This was at the expense
of steroid-induced side effects, most notably a decrease in bone
density and a faster progression to osteoporosis. 5,8
Recent guidelines from the National Institute for Clinical
Excellence recommend that pulmonary rehabilitation is made
available to those patients who would benefit.  Pulmonary
rehabilitation involves a multidisciplinary team consisting of
respiratory physiotherapists, nurses, occupational therapists,
a dietician, a smoking cessation adviser, a social worker, a
pharmacist and a respiratory physician. Until recently the effects
of early pulmonary rehabilitation had not been studied.  A study
carried out in a London hospital involving 42 patients has shown
that early pulmonary rehabilitation after admission to hospital
for acute exacerbations COPD is safe and improves the clinical
outcome of patients at three months.  Further studies are needed
to define the long term effects of this treatment. 6
Thromboembolic lung disease
Diagnosis of pulmonary embolism may be difficult, as
clinical manifestations are often non-specific.  The first methods
of diagnosis were designed to confirm the presence of emboli
while newer techniques focus on excluding pulmonary
embolism.  Various methods used to diagnose or exclude
embolism include the following:
Pulmonary angiography: In a large study conducted the
failure rate of this method was estimated at 0.8%.  The failure
rate was defined as the number of patients with symptoms of
thromboembolic disease who had falsely negative results on
diagnostics tests.  Patients were followed up for a period of three
months from the time of diagnostic testing.
Lung scintigraphy: Studies have revealed a failure rate of
0.9% for this test.   Adding compression ultrasonography or
impedance plethysmography to scintigraphy did not increase
the accuracy of a normal perfusion scan.
D-Dimer alone or combination of D-Dimer and clinical
probability:  In two studies a normal D-Dimer level on ELISA
(enzyme-linked immunosorbent assay) was used to exclude
pulmonary embolism and was found to have a sensitivity and
negative predictive value of 98% to 100%.  Other studies used
D-Dimer assays to exclude pulmonary embolism in patients with
low or moderate clinical probability of embolism.  ELISA and
whole-blood agglutination assays had a sensitivity and negative
predictive value of nearly 100%.
      Spiral Computed Tomography and Compression
Ultrasonography: The combined failure rate for these methods
was found to be 1.8% in one study. This reveals newer, easier
and more cost-effective methods for excluding pulmonary
embolism in certain clinical situations. 7
Pulmonary hypertension
Pulmonary hypertension is characterised by an increase in
pulmonary vascular resistance and increased pulmonary arterial
pressure leading to decreased exercise tolerance and right-sided
heart failure.  The disease can be either primary or secondary
to  other conditions, such as connective tissue diseases,
congenital heart disease causing a left to right shunt, drugs and
HIV infection. 9
Pulmonary hypertension may be classified as follows:
• Stage 1: There is a raised pulmonary arterial pressure but
the patient is asymptomatic (New York Heart Association
stage 1).
• Stage 2: The patient is dyspnoeic on exertion (New York
Heart Association stages 2 and 3).
• Stage 3: The patient is dyspnoeic at rest (New York Heart
Association stage 4). 9
The BREATHE-1 study, (Bosentan Randomised Trial of
Endothelin Antagonist Therapy) analysed the effects of the
endothelin-receptor antagonist bosentan on primary pulmonary
hypertension and that secondary to connective tissue disease.
Patients classified as stage three were enrolled in the study.
These were patients who had been on more traditional treatment
such as oxygen therapy, anticoagulants and calcium channel
blockers.  A double-blind placebo-controlled study was
conducted which included 213 patients who received the
placebo, 125mg bosentan bd or 250mg bosentan bd for twelve
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weeks.  48 of the 213 patients received the placebo or the
endothelin antagonist for a total of twenty-four weeks.
After sixteen weeks of treatment with bosentan it was noted
that patients improved from stage three to stage two.
Improvement lasted twenty weeks and was more marked in
patients with primary pulmonary hypertension and in those who
received the 250mg bd dosing of bosentan.  The drug may be
administered orally, contributing to easy administration, but
monthly checks of liver enzymes are advised since a dose-related
elevation of liver aminotransferase levels was reported.
Bosentan is teratogenic and also interacts with cyclosporin. 9,10
In another study the role of the synthetic salt of prostacyclin
epoprostenol was studied.   A retrospective cohort study
conducted included patients with primary or secondary
pulmonary hypertension who either had a 20% decrease in mean
arterial pressure on acute vasodilator testing or had not
responded to calcium channel blockers.
Epoprostenol was administered as an intravenous infusion
to a mean dose of 23ng/kg/min at 12 months.  The study
included 91 patients and the average follow-up was 2.4 years.
Pulmonary arterial pressure decreased by 15%, pulmonary
vascular resistance decreased by 38% and cardiac output
increased by 25% in the 62 patients who were followed-up.
Survival rates were 79%, 70% and 59% at 1, 2 and 3 years
respectively.  It was also noted that patients with primary
hypertension fared best while those with a connective tissue
disease, older patients and those in stage 3 had a poorer response
to treatment.  Drawbacks of the drug include its high price and
its short half-life necessitating a continuous infusion to ensure
efficacy. 9,11
Other trials conducted in Europe and the United States have
studied the role of other prostacyclin analogues, including
trepostinil, a subcutaneous agent, beraprost, which is orally
administered, and the drug iloprost which may be given via the
inhaled route.  In the studies patients from both stages two and
three (as classified above) were included.  All were associated
with clinical improvement. 9,12
In conclusion, patients with pulmonary hypertension should
be anticoagulated.  Those with a vasodilatory response on
vasoreactivity testing should receive a trial of calcium channel
blockers, notably nifedipine or diltiazem.  Those who do not
respond and are in stage 1 (NYHA) may be regularly monitored.
For those who are unresponsive to the older treatment and are
in stage 2 (NYHA) trepostinil is indicated though bosentan may
also be effective.  The latter is preferred for those with class 3
(NYHA) disease except for those who are severely ill.  In these
patients eprostonol is indicated.  The latter is also indicated in
those with class 4 disease. 9,12
Acute respiratory distress syndrome (ARDS)
A study carried out by Angus et al on previously healthy
survivors of ARDS revealed a poor quality of life during the first
year of survival and up to 50% had respiratory symptoms
suggesting the presence of irreversible lung damage.  The
patients also complained of other symptoms, such as unexpected
weakness, anxiety, depression, insomnia, cognitive impairment
and a reduction in social activity.  This revealed the need for
counselling and neurorehabilitation in such patients. 8,13
Treatment of latent tuberculosis
The American Thoracic Society and the Centres for Disease
Control and Prevention in the United States recommend
reserving tuberculin testing for patients who are at risk for
developing tuberculosis and are candidates for treatment of
latent infection if they test positive.
It is recommended that skin tests are interpreted at 48 to
72 hours.  For high risk patients an area of induration greater
than 5 mm in diameter should be considered to be a positive
result, thus increasing sensitivity and specificity.  High risk
patients are those with HIV disease, people with recent contact
with patients suffering form tuberculosis, patients with evidence
of inactive TB on Chest X-ray and the immunosuppressed.
Patients at intermediate risk include recent immigrants from
countries where tuberculosis is endemic, such as the African
and Asian continents, intravenous drug abusers, health care
workers working in areas such as the inner cities, nursing homes
and prisons and patients with chronic disease, such as insulin-
dependent diabetes mellitus.  For these people an area of
induration of 10 mm or more will give the best specificity.  The
authors do not recommend screening large populations, but if
this were to be done an area of induration of 15 mm or more is
considered to give the best specificity for low risk people.
The preferred regimen for latent tuberculosis is isoniazid
daily or twice weekly for nine months.  Monitoring for side
effects is recommended.  Those receiving the twice weekly
regimen should undergo directly observed therapy.  The authors
allow the course of treatment to be shortened to six months
should any financial difficulties or problems with access to
healthcare arise.
Patients intolerant of isoniazid or who have isoniazid-
resistant tuberculosis may be given rifampicin and pyrazinamide
daily for two months or rifampicin alone in a once daily dose
for four months.  The combination of rifampicin and
pyrazinamide has reportedly caused severe liver injuries and
death, with patients suffering from liver disease being
particularly at risk.  Caution is therefore advised with the above
combination.
It is also recommended that patients receiving treatment
are visited monthly to reinforce compliance and check for side
effects.  Current guidelines recommend liver function testing
prior to and during treatment in patients at risk for liver disease.
Routine liver function testing and serial monitoring in
asymptomatic individuals receiving therapy was deemed
unnecessary.
Thus the role of the primary care physician and public health
officers in the prevention of active tuberculosis is well-
established. 8,14
Sleep apnoea
The relationship between disordered sleep and blood
pressure was studied further when Bixler et al selected 1741 men
and women to undergo a medical history, physical examination,
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psychometric testing and overnight polysomnography.  In the
study, moderate to severe sleep apnoea was defined as an
apnoea-hypopnoea index of more than 15 events per hour during
overnight polysomnography.
Men with moderate or severe sleep-disordered breathing
were found to have a higher incidence of hypertension.  The
study revealed 59.3% (95% confidence limit, 44% to 73.1%) of
the above to have high blood pressure compared with 25.4%
(confidence limit, 21.5% to 29.7%) of men with no sleep
disorder.8, 15  It was further noted that patients with the mildest
form of sleep-disordered breathing, that is snoring alone were
at a higher risk of developing hypertension (odds ratio, 1.56,
[confidence limit, 1.09 to 2.20]) 8,15
As sleep-disordered breathing is emerging as an
independent risk factor for hypertension, researchers are trying
to decipher whether the treatment of sleep apnoea decreases
blood pressure. One such study was carried out by Facenda et al
who randomly assigned 66 normotensive adults with
symptomatic sleep apnoea to receive titrated continuous
positive airway pressure (CPAP) or an oral placebo.  It was noted
that those assigned to the group receiving CPAP had a small
but significant decrease in 24-hour diastolic pressure compared
to the placebo group (mean [± SE]: CPAP group, 77.8 ± 1.0mm
Hg; placebo group, 79.2 ±0.9 mm Hg; P = 0.04).  The differences
were greatest between 2:00 a.m. and 10:00 a.m., thus
supporting the hypothesis that sleep apnoea leads to
intermittent hypoxaemia and subsequent catecholamine release
and an increase in blood pressure which is worse in the early
hours of the morning. It must be pointed out that the study was
criticised for using an oral placebo rather than a mask. The
clinical significance of these observations is still unknown but
it does shine further light on to the relationship between
disordered sleep and blood pressure control. 8,16
NICE guidelines for diagnosis
and treatment of lung cancer
The guidelines issued by the National Institute for Clinical
Excellence (NICE) are aimed at improving the survival rates
among patients diagnosed with lung cancer.  Survival rates in
the UK are 5% lower than the European average and 7-10% lower
than the United States.
NICE recommends urgent referral for chest radiography for
anyone with haemoptysis or unexplained or persistent
symptoms, such as cough, chest pain, dyspnoea or weight loss.
Patents with lesions on chest x-rays or computed tomograms
suggestive of lung cancer should be referred urgently to a chest
physician working as part of a multidisciplinary team.
The guidelines emphasize the need for every cancer network
to have rapid access to 18F-deoxyglucose positron emission
tomography (FDG-PET) for better staging of lung cancer.  They
also recommend cancer units having specialist nurses trained
in lung cancer who will assist the patient both before and after
diagnosis.
The use of modern, evidence based treatments was also
stressed.  Patients with non-small cell lung cancer at stages 1 or
2 who are deemed inoperable should undergo continuous
hyperfractionated accelerated radiotherapy (CHART) rather
than the standard form.  The former is an intensive form of
radiotherapy delivered three times a day for a period of just
over two weeks. The use of chemotherapy was recommended
for non-small cell lung cancer patients at stages 3 and 4 who
are relatively well in order to improve survival, disease control
and quality of life. 17
In conclusion there have been several remarkable advances
in our understanding of the aetiology, pathology and treatment
of a myriad number of diseases of the respiratory system over
the last few years, the treatment of which has significantly
contributed to decreasing morbidity and mortality for our
patients.
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